<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04064034</url>
  </required_header>
  <id_info>
    <org_study_id>19-004658</org_study_id>
    <nct_id>NCT04064034</nct_id>
  </id_info>
  <brief_title>ALateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer</brief_title>
  <official_title>Evaluation of the Diagnostic Potential a Lateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers have developed a new test to measure a protein QSOX1 that is found to be elevated
      in subjects with pancreas cancer. Researchers are looking to use this test to compare
      subjects with pancreas cancer and subjects without pancreas cancer to see if this test could
      be used to diagnosis pancreas cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quiescin Sulfhydryl Oxidase 1 (QSOX1) in the blood</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of subjects with the presence and concentration of QSOX1 peptide found in the blood samples by the lateral flow assay (LFA) test</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pancreas Cancer</condition>
  <condition>Pancreas Cyst</condition>
  <arm_group>
    <arm_group_label>Subjects with pancreas cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will have blood collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with non-cancerous disorders</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will have blood collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with pancreas cyst</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects already undergoing biopsy of a pancreas cyst will have cyst fluid collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lateral Flow Assay (LFA)</intervention_name>
    <description>Test to detect the Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein</description>
    <arm_group_label>Subjects with non-cancerous disorders</arm_group_label>
    <arm_group_label>Subjects with pancreas cancer</arm_group_label>
    <arm_group_label>Subjects with pancreas cyst</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with biopsy-proven adenocarcinoma prior to receiving any therapy such
             as surgery, radiation or chemotherapy.

          -  Patients without pancreas cancer.

          -  Adult patients with benign pancreas disorders such as pancreatitis with imaging within
             12 months (CT, MRI, EUS) documenting no cancer.

          -  Healthy adults with blood specimens in an existing biobank.

          -  Patients with pancreatic cystic lesions.

          -  Adult patients undergoing clinically indicated EUS-guided FNA biopsy of pancreatic
             cystic lesions.

        Exclusion Criteria:

          -  Prior treatment for pancreas cancer.

          -  Unable or unwilling to give consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Faigel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas O Faigel, MD</last_name>
      <phone>480-301-6990</phone>
      <email>faigel.douglas@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 19, 2019</study_first_submitted>
  <study_first_submitted_qc>August 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2019</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Douglas O. Faigel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Pancreatic Cyst</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

